LDS/Medical Tests/Cancer Antigen (CA) 19-9, Serum

Cancer Antigen (CA) 19-9, Serum

Cancer antigen 19-9 (CA 19-9) is a cell surface protein that is shed by certain tumor cells, making it useful as a tumor marker to follow the course of some cancers. Originally this test was developed to monitor colon cancer but it has been proven very sensitive for pancreatic cancer. Very early stages of the cancer can show normal values of the test. CA 19-9 is elevated in most patients with advanced pancreatic cancer, but it may also be elevated in other cancers and conditions including colorectal cancer, lung cancer, biliary and gallbladder cancer, gallstones, pancreatitis, pancreatic cysts and pseudocysts, cystic fibrosis, and liver disease. Bile duct obstruction/cholangitis may also cause very elevated CA 19-9 levels, which fall when the blockage is cleared. The clinical management of pancreatic cancer is extremely difficult with most having metastasized by the time of diagnosis. Monitoring the progression of disease is critical in management; thus serial monitoring of CA 19-9 levels is valuable as an adjunct to imaging and clinical assessment in the management of pancreatic cancer patients. CA 19-9 is neither sensitive nor specific enough to be considered useful as a tool for cancer screening because by the time symptoms develop that would prompt the test the disease is usually in advanced stages.

Note: Patients known to be genetically negative for the Lewis blood group antigens will be unable to produce the CA 19-9 antigen even in the presence of malignant tissue because CA19-9 is a modified Lewis blood group antigen. Measurements of CA 19-9 should always be used in conjunction with other diagnostic procedures.

  • May help to differentiate between cancer of the pancreas and bile ducts and other non-cancerous conditions, such as pancreatitis and pseudocysts
  • Monitoring and management of pancreatic cancer

Elevated in:

  • Pancreatic cancer
  • Slightly elevated in colorectal cancer
  • Slightly elevated in lung cancer
  • Slightly elevated in gallbladder cancer, gallstones, pancreatitis, and pancreatic pseudocysts
  • Also slightly elevated in cystic fibrosis and liver disease/cirrhosis.
  • CA 19-9 is not specific and should not be used as a screening test for cancer

<35 U/mL

 

 

Enzyme Immunoassay

Serum (SST). 

Stability

  • Ambient - 3-5 days
  • Refrigerated - 7 days
  • Frozen - 60 days
Amylase, Lipase, Bilirubin, Carcinoembryonic antigen (CEA), CA 15-3, CA 125, Comprehensive metabolic panel, CBC, Lipid profile, Liver profile, Lewis blood group antigen.
Usually same day.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login